Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary...

Area of Science:

• Cardiology
• Interventional Cardiology
• Hematology

Background:

• Patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) benefit from abbreviated dual antiplatelet therapy (DAPT).
• Optimal DAPT duration in specific subgroups, like anemic patients, remains unclear.
• Anemia is a significant factor influencing cardiovascular outcomes and bleeding risk after PCI.

Purpose of the Study:

• To evaluate the safety and efficacy of abbreviated DAPT (1 vs. 3 months) in HBR patients undergoing PCI, with a specific focus on anemic subgroups.
• To determine if a shorter DAPT duration impacts ischemic versus bleeding events in anemic HBR patients.

Main Methods:

• Analysis of 3,364 HBR patients from prospective trials using cobalt-chromium everolimus-eluting stents.
• Anemia defined as hemoglobin <11 g/dL.
• Propensity score stratification used to compare outcomes between 1-month and 3-month DAPT durations, assessing all-cause death, myocardial infarction, and major bleeding (BARC 2-5, 3-5).

Main Results:

• Anemic patients (15.3%) had higher ischemic and bleeding event rates at 1 year compared to non-anemic patients.
• In anemic patients, 1-month DAPT showed similar ischemic outcomes (15.7% vs. 16.3%) but significantly lower major bleeding rates (6.1% vs. 11.1%) compared to 3-month DAPT.
• Non-anemic patients showed similar ischemic and bleeding outcomes regardless of DAPT duration.

Conclusions:

• Abbreviated DAPT in HBR PCI patients yields comparable ischemic outcomes across anemia statuses.
• A 1-month DAPT regimen in anemic HBR patients significantly reduces major bleeding without a discernible increase in ischemic risk.
• Shortened DAPT appears to be a viable strategy for managing bleeding risk in anemic patients post-PCI.